Daniel Brodie

TL;DR: The peer-reviewed and preprint literature pertaining to cardiovascular considerations related to COVID-19 are reviewed to highlight gaps in knowledge that require further study pertinent to patients, health care workers, and health systems.

TL;DR: Information about a real patient is presented in stages (boldface type) to expert clinicians (Drs Uriel and Sayer), who respond to the information and share their reasoning with the reader (regular type).

TL;DR: Estimating the posterior probability, under various assumptions, that early ECMO was associated with reduced mortality in patients with very severe ARDS in a randomized clinical trial (RCT) provides information about the posterior probabilities of mortality benefit under a broad set of assumptions that may help inform interpretation of the study findings.

TL;DR: The latest generation of ECMO systems is more biocompatible, better performing and longer lasting, and although recent studies suggested that veno-venous ECMO might improve the outcomes of patients with ARDS, indications for ECMO use remain uncertain.

TL;DR: The severity LVD was inversely related to the likelihood of myocardial recovery, and event-free survival was diminished in LVD++ and LVD+ patients compared with LVD−.